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Introduction 
 
Stem and progenitor cells are less specialized 
cells that have both the ability for self-renewal 
and the potential to differentiate into special-
ized cells in response to specific signals [1]. 
Mesenchymal stem cells (MSCs) are derived 
from a population of stromal cells present in 
bone marrow and various tissues, which also 
can differentiate into different tissue lineages [2
-4]. In the last decade, it has been well estab-
lished that MSCs have the ability to differentiate 
various cell types encompassing osteoblasts, 
chondrocytes, myocytes, marrow stromal cells, 
tendon-ligament fibroblasts, adipocytes, and 
other mesenchymal phenotypes [5], suggesting 
their use as a source of cells for various applica-
tion of regenerative medicine. In addition to 
their potentials, understanding the fundamental 
mechanisms to control cell fate and function is 
a critical step to translational application of 
MSCs. In many studies, stem cell fate and func-
tion have been generally controlled by 
“cocktails” of growth factors, signaling mole-
cules, and/or genetic manipulations [6, 7]. How-
ever, the composition and/or conditions of most 
of these cocktails are not exactly defined and 
they do not specifically regulate stem cell fate, 
resulting in heterogeneous population of cells. 
Because cell-based therapies may require large 
quantities of stem cells for clinical uses, it 
would be advantageous to isolate specific small 
molecules that either maintain self-renewal or 
drive tissue specific fates of stem cells [8]. In 
addition, virus-mediated genetic manipulation 
introduces unacceptable risks of permanent 
transgene integration to the genome. The result-
ing genomic alteration and possible reactivation 
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of viral transgenes pose serious clinical con-
cerns [9].  
 
Small molecules have shown to be useful tools 
for modulating cell fate and function by target-
ing specific signals and mechanisms [10-12]. In 
addition, they provide some distinct advantages 
over other techniques, such as gene manipula-
tion, preconditioning, and pretreatment with 
effectors including growth factors and cytokines 
that are fast, reversible, and precise temporal 
regulators of protein function [10]. Indeed, vari-
ous cell permeable small molecules have been 
proven to be clearly useful for inducing the dif-
ferentiation of various stem cells including 
MSCs. Moreover, the immense potential of 
orally delivered small molecules as regenerative 
therapies are now widely recognized [13]. In this 
review, we focus on recent advances in the use 
of small molecules to control MSCs fates such 
as proliferation, differentiation, and functional 
activity.  
 
The control of cell fate by small molecules  
 
Small molecules 
 
Small molecules have been synthesized and 
tested in phenotypic analysis to screen biologi-
cally useful molecules for over 100 years [14]. 
Although one compound was tested at a time in 
the earliest era, modern libraries contain thou-
sands and even millions of small molecules that 
are synthesized through combinatorial chemis-
try and tested by high-throughput screening 
techniques [14]. The complementary approach 
to classical genetics, where small molecules are 
exploited to probe biological functions, is 
termed “chemical genetics” [15, 16]. While 
classical genetics establishes genotype-
phenotype relationships through means of ge-
netic manipulation, chemical genetics uses 
small molecules that intervene in signaling 
pathways through direct interaction with pro-
teins to unravel relationships between proteins 
and phenotypes. By analogy to classical genet-
ics, small compounds in chemical genetics are 
equivalent to mutations in classical genetics 
[17]. In fact, given that chemicals can be re-
moved from cells by simple washing, they are 
analogues to conditional mutations. Although 
small molecules allow reversible temporal and 
dose-dependent control of protein function, one 
of their major limitations is that a single com-
pound often affects multiple proteins and sub-
sequently multiple pathways [18, 19]. Thus, 
treatment with a single small molecule can be 
analogous to simultaneous modulations in sev-
eral genes.  
 
The method of using small molecules to modu-
late and control the stem cell fate has a long 
history. Indeed, all-trans-retinoic acid has been 
used for over 30 years to induce differentiation 
of both mouse and human embryonal carci-
noma cells [20, 21]. Hexamethylenebis-
acetamide and DMSO also have been used to 
promote differentiation of embryonal carcinoma 
cells and erythroleukemia cells, respectively 
[22, 23]. In addition, stem cells share many 
properties with tumor cells and these similari-
ties can provide insights to control and direct 
cell behavior. Indeed, small molecules are al-
ready standard chemotherapeutics in the treat-
ment for cancer [8]. A number of small mole-
cules have been examined for anti-cancer ef-
fects (especially induction of apoptosis), and 
recently, for stem cell self-renewal and specific 
differentiation in potential approaches to regen-
erative medicine. Indeed, both natural and syn-
thetic small molecules have been shown to be 
useful chemical tools for manipulating the fates 
of cells [8].  
 
Modulation of stem cell fate by small molecules  
 
As mentioned above, small molecules have 
been used to modulate and/or control cell fate, 
and behavior, especially stem cells, for a long 
time. In fact, most of the studies that are cur-
rently being conducted and/or are ongoing in 
this field focus on the revealing the mecha-
nisms of self-renewal and differentiation of em-
bryonic stem cells (ESCs) and the generation of 
induced pluripotent stem cells (iPSCs) [8, 24]. 
Indeed, various small molecules have been 
identified to regulate the differentiation and self
-renewal of ESCs. For example, Pluripotin, 
CHIR99021, and A83-01 can support self-
renewal of ESCs through targeting the RasGAP, 
GSK-3, and ALK5 signaling pathways, respec-
tively [25-27]. (-) Indolactam V can enhance the 
pancreatic differentiation of ESCs through PKC 
pathway, and stauprimide and SB431542 in-
duces differentiation of ESCs through NME2 
and ALK5 pathways [28, 29]. In addition, sev-
eral small molecules were revealed to affects 
somatic cell reprogramming. BIX-01294, 
RG108, and parnate can promote MEFs repro-
gramming through regulating G9a HMTase, DNA 
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MTase, and lysine-specific demethylase, respec-
tively [10, 30, 31]. Interestingly, a small mole-
cule, Reversine, can induce dedifferentiation of 
muscle and fibroblast cells into a more primitive 
multipotent state [32-34].  
 
Regulation of differentiation in MSCs by small 
molecules 
 
Mesenchymal stem cells: A brief overview 
 
MSCs are a heterogeneous subset of stromal 
cells that are classically derived from bone mar-
row [2]. But they have been isolated from most 
connective tissues including adipose tissue 
[35], periosteum [36], and synovial membrane 
[11]. MSCs have apparent advantages, such as 
easy availability, few ethical concerns, and low 
immunogenicity, compared to embryonic stem 
cells and other tissue-specific stem cells. In-
deed, because MSCs can be easily isolated and 
expanded in culture, they can be administered 
immediately instead of waiting weeks and/or 
months for adequate numbers of cells to be 
achieved by cell culture. MSCs retain their 
growth and multilineage potential over several 
passages, although they are moral [37, 38]. In 
addition to their multilineage trans-
differentiation potential, one particularly useful 
characteristic of MSCs is their apparent im-
munoprivilege. They display local immunosup-
pressive properties that permit successful trans-
planting in an allogenic setting. Indeed, experi-
ments in non-human primates have shown that 
allogenic MSCs were not rejected but showed 
similar effects on the autologous MSCs and 
were detected nine months after transplanta-
tion in the recipient [39-41].Overall, these stud-
ies have suggested MSCs as an attractive candi-
date cell type for tissue engineering, regenera-
tive medicine, and autoimmune disease treat-
ment. 
 
Specific differentiation of MSCs by small mole-
cules 
 
For practical use of stem cells for regeneration 
therapy, there are at least three prerequisites: 
(i) the directed differentiation of stem cells to 
specific cell types, (ii) achievement of high sur-
vival rate of the cells after transplantation, and 
(iii) prevention of undifferentiated stem cells 
that are prone to form teratomas and/or can-
cers [42]. Amongst them, the ex vivo directed 
differentiation of stem cells to specific cell types 
for treating target diseases may provide better 
clinical results. Classically, osteogenic differen-
tiation of human MSCs requires incubation in 
fetal bovine serum (FBS)-containing medium 
supplemented with ascorbic acid, -
glycerophosphate, and dexamethasone, result-
ing in an increase in alkaline phosphatase activ-
ity and calcium deposition [43, 44]. The chon-
drogenic differentiation is performed with a high 
cell-density pellet or a micromass culture 
treated with transforming growth factor (TGF)- 
in a serum-free medium; this results in the pro-
duction of cartilage-specific, highly sulfated pro-
teoglycans and type II collagen [45]. For adipo-
genic differentiation, MSCs are treated with FBS 
containing medium supplemented with dexa-
methasone, insulin, isobutyl methyl xanthine, 
and indomethacin. The differentiation is de-
tected bythe oil red O staining for lipid vacuoles 
[45]. In addition to these reports, many studies 
have shown that a number of small molecules 
can be used to control the fate of MSCs for a 
variety of applications. For example, 5-
azacytidine (5-aza-C) can induce murine and 
human bone marrow stromal cells into cardio-
myocytes [46-48], and also induce mouse mes-
enchymal progenitor cell line, C3H10T1/2 cells, 
into myoblast, osteoblasts, adipocytes, and 
chondrocytes (Table 1) [43]. It has been re-
vealed that 5-aza-C does not directly induce or 
activate the specific differentiation pathways of 
MSCs, but rather convert the cells into a compe-
tent spontaneous differentiation state [49]. 
However, recent reports showed that 5-aza-C-
treated human mesenchymal stem/progenitor 
cells derived from umbilical cord, cord blood 
and bone marrow do not generate cardiomyo-
cytes in vitro at high frequencies [50, 51]. This 
suggests that the induction of specific differen-
tiation by small molecules might be dependent 
on cell types. All-trans retinoic acid is one of the 
prominent molecules that has long been in con-
trol of cell fate. Recently, it was reported that 
retinoic acid may induce chondrogenesis, os-
teoblastogenesis, and neuronal differentiation 
of MSCs [52-54]. Peroxisome proliferator acti-
vated receptor  (PPAR) agonist and antago-
nists are used as adipogenesis modulators [55, 
56]. Dexamethasone, ascorbic acid, and -
glycerophosphate can also be used to induce 
osteogenesis or adipogenesis of MSCs under 
defined conditions (Table 1) [43, 57].  
 
To identify small molecules that selectively dif-
ferentiate MSCs into defined-lineages, we 
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screened a small library (41 compounds) of 
characterized and commercially available inhibi-
tors of six major subfamilies of protein kinases 
that are known to inhibit various cellular proc-
esses: TK (tyrosine kinase families), TKL 
(tyrosine kinase-like families), CMGC (CDK, 
MAPK, GSK3, CLK families), CAMK (Ca/
calmodulin dependent protein kinase), AGC 
(PKA, PKG, and PKC families), and CKI (Casein 
kinase family) [58]. Because such important 
cellular processes are likely to be controlled by a 
complicated orchestration of many signaling 
pathways including many undiscovered ones, 
common signal modulators, such as protein 
kinases, are likely to play an important role in 
balancing multiple signals affecting several as-
pects of the above prerequisites [42]. Protein 
kinases belong to one of the largest protein 
families in the human genome, and they play 
critical roles in signaling pathways implicated in 
the development, differentiation, proliferation, 
and death of cells. Several signaling pathways 
have been known to induce or suppress differ-
entiation of stem cells, such as the pathways 
involving mitogen-activated kinases, glycogen 
synthase kinase-3, PI3-kinase, and others [24, 
44, 59-61]. A glycogen synthase kinase 3(GSK-
3) inhibitor synthesized by combinatorial 
chemistry has been shown to induce neuro-
genesis [24]. In this study, among several candi-
dates that drive rat MSCs into specific cell 
types, H-89, an inhibitor of protein kinase A, was 
found to be potentially implicated in chondro-
genesis of the MSCs, which is a derivative of 
isoquinolinesulfonamide, N-[2-((p-bromocinn-
amyl)amino)ethyl]-5-isoquinolinesulfonamide, 
2HCl [42]. We also found that H-1152, a Rho 
kinase inhibitor, was the best inducer of differ-
entiation of ESCs into tyrosine hydroxylase (TH), 
a catecholaminergic neuronal marker, -positive 
neurons. H-1152 is another cell-permeable iso-
quinoline sulfonamide derivative that acts as a 
highly specific, potent, and ATP-competitive in-
hibitor of G protein ROCK (Ki=1.6 nM) [42]. 
Based on the above results, the enhanced dif-
ferentiation of rat MSCs to specific lineages sup-
port the notion that, although cell differentiation 
may be the result of a complex orchestration of 
many signals from multiple signaling pathways, 
even a single chemical reagent is enough to 
alter the relative balance of many signals to 
enhance differentiation of stem cells to particu-
lar cell types. They also suggest that the process 
may be optimized by a ‘‘mixture’’ of various mul-
tiple kinase inhibitors as well as other kinds of 
small molecules. Because these compounds 
may interact with ‘‘off-target’’ kinases as well as 
other unknown proteins, our observation should 
be considered as a practical approach to finding 
chemical reagents for inducing stem cell differ-
entiation to a specific cell type even when most 
of the signaling pathways are unknown [42]. 
Thus, the approach described or some variation 
of it may be applied to other stem cells, includ-
ing human stem cells, to find chemical mole-
cules that can trigger initiation, inhibition, or 
even reversion of the differentiation process of 
stem cells or progenitor cells. 
 
In recent studies, we found that phorbol 
myristate acetate (PMA), a PKC activator, and 
can upregulate cardiogenic properties from 
MSCs and subsequently chemically activated 
cardiogenic MSCs preventing sudden deaths 
after engraftment onto infarcted rats by electro-
mechanically synchronizing with the host myo-
cardium [62]. These suggest that small mole-
cules may regulate the stem cell functions as 
well as the fate. In addition, we also found that 
a kind of glycogen synthase kinase-3 (GSK-3) 
inhibitor may induce the endothelial differentia-
tion of MSCs in recent studies, which might be 
an important implication for treating vascular 
diseases (unpublished).  
 
Wu et al. also identified a small molecule that 
selectively differentiates MSCs into osteogenic 
lineages through screening a combinatorial het-
erocyclic compound library in the mouse mesen-
chymal progenitor cells [63]. Purmorphamine, 
2,6,9-trisubstituted purine compound, was iden-
tified as a potent osteoblast differentiation in-
ducing agent that can activate Cbfa1/Runx2 (a 
key regulator of bone development) as well as 
upregulate other bone specific markers, such as 
osteopontin and collagen I. In addition, it was 
reported that decalpenic acid, a novel small 
molecule from Penicilliumverruculosum 
CR37010, induces early osteoblastic markers in 
mouse C3H10T1/2 cells [64]. Pevsner-Fischer 
et al. reported that toll-like receptors are associ-
ated with MSCs function and their inhibitor, 
Pam3Cys, increases MSC proliferation and in-
hibits MSC differentiation into chondrocytes, 
osteocytes, and adipocytes (Table 1) [65].   
 
Concluding remarks 
 
Although substantial growth arose in recent 
years, stem cell research and development are 
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still in an early stage. The control of stem cell 
fate and function is an important step for clini-
cal applications of stem cells in regenerative 
medicine. In addition to the focus on pluripotent 
stem cells including ESCs and iPSCs, under-
standing and controlling the fate and function of 
adult stem cells such as, MSCs, in vitro and in 
vivo might be a significant challenge for devel-
oping better therapeutic approaches to regen-
erative medicine. Among various approaches in 
controlling stem cell fate, small molecules are 
considered as the best tool in the next era, be-
Table 1. Small molecules in controlling the fate of mesenchymal stem cells 
Structure Name Target pathway Effects Results 
 
  
5-azacytidine 
  DNA methyltrans-
ferase inhibition 
Promotes cardiomyogenic, 
adipogenic differentiation
[46, 48, 67] 
   
all-trans retinoic acid 
  
Smad/p38 
  
Regulation of DNA 
transcription 
  
Induces chondrogenesis , 
osteoblastogenesis, and 
neuronal differentiation [52-
54] 
 
  
dexamethasone 
  
  
  
Increases alkaline 
phosphatase activity 
and enhances cal-
cium deposition [68] 
  
Increases the effect of 5-aza 
and induces differentiation 
program [57] 
 
  
ascorbic acid 
  
  
  
Increases alkaline 
phosphatase activity 
  
Induces adipogenesis or 
osteogenesis [43] and en-
hance proliferative activity 
[69] 
 
  
rosiglitazone 
  
  
  
PPARγ activation 
  
Adipogenesis modulation 
[55, 56] 
 
  
Pam3cys 
  
NF- κB 
  
TLR inhibition 
Increases MSCs proliferation 
and inhibits MSCs differen-
tiation into chondrocytes, 
osteocytes, and adipocytes
[65] 
 
  
purmorphamine 
  
Hedgehog 
  
Smo inhibition 
  
Induces osteogenesis [70] 
 
H-89   Protein kinase A 
inhibition 
Induces chondrogenesis [42] 
 
SB216763 Wnt GSK-3β inhibition Induces endothelial differen-
tiation 
 
phorbol myristate ace-
tate 
  Protein kinase C 
activation 
Induces cardiomyogenic 
differentiation [62] 
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cause small molecules can target signaling 
transduction pathways (for example, tyrosine 
kinase receptors) and affect various cellular 
events, such as, DNA replication, differentiation, 
proliferation, and apoptosis. Obviously the field 
is interdisciplinary and involves chemists, a 
range of biologists, and bioinformaticians. In-
deed, chemists have to build small molecule 
libraries based on the structural motifs of 
known and/or potential regulators in specific 
pathways, and stem cell biologists may have to 
study to better understand the molecular inter-
actions between small molecules and specific 
behaviors of stem cells. Small molecules are 
also important tools for understanding mecha-
nistic and developmental processes because 
they can be added or removed at any point dur-
ing development while mutations tend to persist 
throughout the organism’s life [8]. Such tempo-
ral control is critical in understanding the spe-
cific timing of developmental processes [66]. 
Because of the current challenges in stem cell 
biology to control stem cell fate and function, 
small molecules might emerge as a powerful 
strategy to identify drugs that may regulate 
stem cell activity and may ultimately be useful 
to in vivo stem cell biology and therapy. 
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